Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents

Publication
Video
Contemporary OB/GYN JournalVol 67 No 3
Volume 67
Issue 3

Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

If approved, relugolix, estradiol, and norethindrone acetate tablets (Myfembree; Myovant Sciences, Pfizer) could be game-changing for pain management in women with moderate-to-severe endometriosis pain.

Recent Videos
Ryan Haumschild, PharmD
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
Updated FLUBLOK label expands influenza vaccine options for pregnant women | Image Credit: mass-vaccination-resources.org
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
JoAnn Pinkerton discusses elinzanetant's crucial role in VMS therapy | Image Credit: uvahealth.com
Elinzanetant displays positive phase 3 safety and efficacy data against VMS | Image Credit: © toeytoey - © toeytoey - stock.adobe.com.
JoAnne Pinkerton, MD, FACOG, NCMP
Nannette Santoro, MD
Learning what women prefer in STI preventive care
Why doxycycline PEP lacks clinical data for STI prevention in women
Related Content
© 2025 MJH Life Sciences

All rights reserved.